11 results
The aim of this study is to accelerate recovery after liver surgery by enhancing intestinal passage through the preoperative use of Movicol®.
The ORANGE-II trial is a randomised controlled trial that will provide evidence on the merits of laparoscopic surgery in patients undergoing a left lateral hepatic sectionectomy and participating in an enhanced recovery programme.
To assess if preoxygenation with 100% O2 or preoxygenation with 100% O2 and PEEP are different with respect to the development of atelectasis as determined by lung computed tomography.
1. To characterize the efficacy of topical Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, in surgical subjects when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical2. To…
To reduce intraoperative blood loss and enhance tolerance of the FRL to I/R injury during right hemihepatectomy under vascular exclusion by means of in situ hypothermic perfusion with retrograde outflow (R-IHP) of the FRL.
1 Primary Objective To investigate the effects of 15* liver ischemia versus 30* liver ischemia on liver injury and liver function.To investigate the effect of liver manipulation during mobilisation for a right hemihepatectomy, that can be used as a…
The purpose of this study is to monitor whether preicncisional bupivacaine (bupivacaïne 0,5% with epinefrine 1:200.000), infiltration in trocarcincisions reduces postoperative wound pain in patients undergoing laparoscopic cholecystectomy.
The objective of the study is to compare free-hand needle placement with navigation guided needle placement.
The purpose of this study is, in a phase II randomized trial, to test a newly developed machine perfusion technique of human liver allografts before transplantation.
The aim is to address the following research question:Is there a higher incidence of postoperative (wound) infections when utilizing maximally hygienic measures instead of sterile measures in elective laparoscopic cholecystectomies?Secondary…
To study the efficacy of end-ischemic DHOPE in reducing the incidence of NAS within six months after controlled DCD (Maastricht category III) liver transplantation.